DUBLIN, Ireland--(Business Wire)--Research and Markets
(http://www.researchandmarkets.com/reports/c78711) has announced the
addition of "SPECIAL REPORT: 2007 Industry Dynamics-Lessons Learned"
to their offering.
Introduction
Moderate successes and "business as usual" characterize the
performance of the pharmaceutical industry in 2007. In this year-end
retrospective report, we contemplate the importance of key events and
achievements in the industry. We asked industry-leading experts to
identify particularly noteworthy events in 2007 and lessons that can
be learned for 2008. Six themes emerged; our experts discuss their
implications for the industry. Furthermore, we offer a Spectrum
Scorecard that assesses industry performance in a variety of critical
areas.
Get the Answers You Need to Shape Your Strategy
- The pharmaceutical industry may never be to return to its glory
days, but it can exert control over its future through the strategies
and changes that it is willing to adopt today. What strategic options
are essential to achieve success in today's evolving markets? What are
the future implications of these changes for pharmaceutical companies?
- Pharmaceutical companies must ensure they are "fit for purpose"
in today's business environment. What strategies can pharmaceutical
management pursue to capture and harness the essence of a result
oriented business and make their companies truly fit for purpose? How
can they uncover previously unrealizable profits and growth and also
differentiate themselves so that they can grasp valuable competitive
advantage?
Scope
- 2007 in review: a retrospective on news and key themes from the
year.
- Seeking a new vision for the pharmaceutical industry: looking
for the Holy Grail of opportunity.
- Negative industry impacts: from generics erosion, biogenerics,
declining productivity, and drug safety
- concerns combined with the increased importance of specialty
pharma and biotech.
- New strategies needed for future success: rethinking the
blockbuster strategy, a holistic approach to
- management style, fit with strategy, choosing strategies and
opportunities wisely.
- Jumping on technology opportunities: identifying key
technologies and turning innovation into
- new products and services.
- New value propositions: value-for-money.
- Growing influence of U.S. states: legislative bills, litigation
by state attorneys general, lessons
- learned.
- 2007 industry report card: how successful was Big Pharma in
capitalizing on the many
- opportunities available in 2007?
List of Key Concepts/Opportunities:
- Best in Class
- Biogenerics/biosimilars
- Biologics
- Biomarker-driven
- Black box warnings
- Blockbuster business model
- Choosing wisely
- Clinical trial registries
- Consolidation
- Consumerism
- Cost/price battle
- Cost-cutting
- Critical success factor (CSF)
- Disruptive technology
- Downsizing
- Drug safety
- First-in-class
- Fit for purpose
- Flexibility
- Flight-of-capital
- Focused strategies
- Free-market economies
- Fully integrated pharmaceutical company (FIPCO)
- Generics erosion
- Globalization
- Growth deceleration
- Holistic approach
- Inlicensing
- Innovation
- Life-cycle management
- Litigation proceedings
- Little Science
- Low-hanging fruit
- Management style
- Managing Risk
- Margins
- Merger & acquisition (M&A)
- Me-too products
- Money-back guarantee
- Monoclonal antibodies
- New chemical entity (NCE)
- New molecular entity (NME)
- Not-invented-here syndrome
- Organizational uncertainty
- Patent expiry
- Personalized medicine
- Pharmacogenomics
- Premium pricing
- Product acquisition
- Protein optimization
- R&D productivity
- Reactive strategies
- Reference pricing
- Resource allocation
- Results-oriented business
- Return on investment (ROI)
- Revolutionary transformation
- Risk averse
- Risk sharing
- RNA interference
- Rx dilemma
- Second-generation products
- Specialty pharma
- State attorneys general
- Stem cells
- Strategic choice
- Targeted therapy
- Technology opportunities
- Transparency
- Unmet need
- Value-added advantage
- Value propositions
- Value-for-money
For more information, visit
http://www.researchandmarkets.com/reports/c78711
Research and Markets
Laura Wood
Senior Manager
Fax: +353 1 4100 980
press@researchandmarkets.com
Copyright Business Wire 2008
